Cathay Biotech Stock Fundamentals
| 688065 Stock | 42.02 0.48 1.13% |
Cathay Biotech fundamentals help investors to digest information that contributes to Cathay Biotech's financial success or failures. It also enables traders to predict the movement of Cathay Stock. The fundamental analysis module provides a way to measure Cathay Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cathay Biotech stock.
At present, Cathay Biotech's Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Net Interest Income is forecasted to decline to about 134.7 M. Cathay | Select Account or Indicator |
Cathay Biotech Company Current Valuation Analysis
Cathay Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cathay Biotech Current Valuation | 21.45 B |
Most of Cathay Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cathay Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cathay Biotech has a Current Valuation of 21.45 B. This is 88.04% higher than that of the Chemicals sector and 54.4% higher than that of the Materials industry. The current valuation for all China stocks is 29.05% lower than that of the firm.
Cathay Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cathay Biotech's current stock value. Our valuation model uses many indicators to compare Cathay Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cathay Biotech competition to find correlations between indicators driving Cathay Biotech's intrinsic value. More Info.Cathay Biotech is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.41 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cathay Biotech is roughly 2.45 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cathay Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cathay Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cathay Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cathay Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cathay Biotech could also be used in its relative valuation, which is a method of valuing Cathay Biotech by comparing valuation metrics of similar companies.Cathay Biotech is currently under evaluation in current valuation category among its peers.
Cathay Fundamentals
| Return On Equity | 0.026 | ||||
| Return On Asset | 0.0106 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 21.45 B | ||||
| Shares Outstanding | 583.38 M | ||||
| Shares Owned By Insiders | 61.34 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Price To Book | 2.18 X | ||||
| Price To Sales | 8.87 X | ||||
| Revenue | 2.11 B | ||||
| Gross Profit | 2.44 B | ||||
| EBITDA | 608.83 M | ||||
| Net Income | 366.52 M | ||||
| Total Debt | 1.53 B | ||||
| Book Value Per Share | 19.74 X | ||||
| Cash Flow From Operations | 569.45 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 69.35 | ||||
| Number Of Employees | 1.8 K | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 24.51 B | ||||
| Total Asset | 18.83 B | ||||
| Retained Earnings | 2.07 B | ||||
| Working Capital | 4.16 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 18.83 B | ||||
| Last Dividend Paid | 0.19 |
About Cathay Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.1 B | 2.3 B | |
| Cost Of Revenue | 1.5 B | 1.4 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Cathay Stock
Cathay Biotech financial ratios help investors to determine whether Cathay Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cathay with respect to the benefits of owning Cathay Biotech security.